Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- Check15 days agoChange DetectedThe page’s revision/version label was updated from v3.5.2 to v3.5.3, indicating a non-clinical site/software update.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision: v3.5.2 replaces the previous v3.5.0.SummaryDifference0.1%

- Check29 days agoNo Change Detected
- Check50 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page header now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check86 days agoChange DetectedThis update shows a minor revision label change from v3.4.1 to v3.4.2. No substantive changes to the study details or eligibility criteria appear to have occurred.SummaryDifference0.1%

- Check94 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous Revision: v3.4.0.SummaryDifference0.1%

Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.